Closely-held Soricimed Biopharma reported that the MD Anderson Cancer Center has resumed its investigator-initiated trial of Soricimed’s SOR-C13.
MD Anderson completed the first cohort of the dose escalation phase of the trial in February 2020. The first cohort focused on late-stage pancreatic cancer patients and demonstrated that SOR-C13 is safe and well-tolerated, with no drug-related adverse events.
Following a temporary suspension due to the COVID-19 pandemic, trial enrollment will now resume, with dosing of the second cohort proceeding at a significantly higher dose level of SOR-C13.
“We are gradually resuming clinical trial activities as more resources are becoming available and, given SOR-C13’s positive safety profile, its potential to treat pancreatic cancer and the speed at which recruitment occurred since the trial began in September 2019, we selected this trial for resumption,” Dr. Siqing Fu, the study’s principal investigator, said in a statement.
“We are looking forward to gathering additional SOR-C13 safety data, followed by early efficacy data in the planned expansion cohort,” he added.
